UK Markets close in 4 hrs 47 mins

PharmaEngine, Inc. (4162.TWO)

Taiwan OTC - Taiwan OTC Delayed price. Currency in TWD
Add to watchlist
193.50+11.41 (+6.27%)
At close: 1:30PM CST
Full screen
Previous close182.09
Bid193.00 x
Ask193.50 x
Day's range186.50 - 195.00
52-week range145.01 - 212.51
Avg. volume655,545
Market cap23.59B
PE ratio (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire9 months ago

    PharmaEngine Announces Onivyde(R) Receives European Marketing Authorization for the Treatment of Metastatic Adenocarcinoma of the Pancreas Following Gemcitabine based Therapy

    TAIPEI, Taiwan, Oct. 18, 2016 /PRNewswire/ -- PharmaEngine, Inc. (TWO: 4162) announced that the European Commission (EC) has granted Shire plc (PharmaEngine's sublicensee, LSE: SHP, NASDAQ: SHPG) a marketing ...

  • PR Newswirelast year

    PharmaEngine Announces ONIVYDE(R) Regimen Receives CHMP Positive Opinion for the Treatment of Metastatic Pancreatic Cancer

    TAIPEI, Taiwan, July 25, 2016 /PRNewswire/ -- PharmaEngine, Inc. (TWO:4162) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization of ONIVYDE® (irinotecan liposome injection, nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine based therapy. The CHMP positive opinion for ONIVYDE will now be reviewed by the European Commission for marketing authorization in the European Union (EU).

  • Reuters2 years ago

    FDA clears Merrimack's pancreatic cancer drug with warning

    The U.S. Food and Drug Administration approved Merrimack Pharmaceutical Inc's pancreatic cancer therapy Onivyde, but with a serious warning, marking the company's first ever drug to win regulatory clearance. The drug in combination with chemotherapy treatments 5-fluorouracil and leucovorin treats metastatic pancreatic cancer in patients, who have failed to respond to chemotherapy drug gemcitabine. Onivyde, however, carries a black box warning about severe risks of diarrhea and low white blood cell count, the agency said, adding that it was not approved for use as a single agent.